TY - JOUR
T1 - Axial Elongation Trajectories in Chinese Children and Adults With High Myopia
AU - Zhang, Shiran
AU - Chen, Yanping
AU - Li, Zhixi
AU - Wang, Wei
AU - Xuan, Meng
AU - Zhang, Jian
AU - Hu, Yin
AU - Chen, Yanxian
AU - Xiao, Ou
AU - Yin, Qiuxia
AU - Zheng, Yingfeng
AU - He, Mingguang
AU - Han, Xiaotong
N1 - Publisher Copyright:
© 2023 American Medical Association. All rights reserved.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - IMPORTANCE Understanding the long-term axial elongation trajectory in high myopia is important to prevent blindness. OBJECTIVE To evaluate axial elongation trajectories and related visual outcomes in children and adults with high myopia. DESIGN, SETTING, AND PARTICIPANTS In this cohort study, participants in the Zhongshan Ophthalmic Centre-Brien Holden Vision Institute high myopia cohort were followed up every other year for 8 years. Participants with axial length measurements at baseline (2011 or 2012) and at least 1 follow-up visit were included. Participants were grouped according to baseline age as children and adolescents (7 to <18 years), young adults (18 to <40 years), and older adults (≥40 to 70 years). Data were analyzed from November 1, 2022, to June 1, 2023. EXPOSURE High myopia (spherical power ≤−6.00 diopters). MAIN OUTCOMES AND MEASURES Longitudinal axial elongation trajectories were identified by cluster analysis. Axial elongation rates were calculated by linear mixed-effects models. A 2-sided P < .05 was defined as statistically significant. RESULTS A total of 793 participants (median [range] age, 17.8 [6.8-69.7] years; 418 females [52.7%]) and 1586 eyes were included in the analyses. Mean axial elongation rates were 0.46 mm/y (95% CI, 0.44-0.48 mm/y) for children and adolescents, 0.07 mm/y (95% CI, 0.06-0.09 mm/y) for young adults, and 0.13 mm/y (95% CI, 0.07-0.19 mm/y) for older adults. Cluster analysis identified 3 axial elongation trajectories, with the stable, moderate, and rapid progression trajectories having mean axial elongation rates of 0.02 mm/y (95% CI, 0.01-0.02 mm/y), 0.12 mm/y (95% CI, 0.11-0.13 mm/y), and 0.38 mm/y (95% CI, 0.35-0.42 mm/y), respectively. At 8 years of follow-up, compared with the stable progression trajectory, the rapid progression trajectory was associated with a 6.92 times higher risk of developing pathological myopic macular degeneration (defined as diffuse or patchy chorioretinal atrophy or macular atrophy; odds ratio, 6.92 [95% CI, 1.07-44.60]; P =.04), and it was associated with a 0.032 logMAR decrease in best-corrected visual acuity (β = 0.032 [95% CI, 0.001-0.063]; P =.04). CONCLUSIONS AND RELEVANCE The findings of this 8-year follow-up study suggest that axial length in high myopia continues to increase from childhood to late adulthood following 3 distinct trajectories. At 8 years of follow-up, the rapid progression trajectory was associated with a higher risk of developing pathological myopic macular degeneration and poorer best-corrected visual acuity compared with the stable progression trajectory. These distinct axial elongation trajectories could prove valuable for early identification and intervention for high-risk individuals.
AB - IMPORTANCE Understanding the long-term axial elongation trajectory in high myopia is important to prevent blindness. OBJECTIVE To evaluate axial elongation trajectories and related visual outcomes in children and adults with high myopia. DESIGN, SETTING, AND PARTICIPANTS In this cohort study, participants in the Zhongshan Ophthalmic Centre-Brien Holden Vision Institute high myopia cohort were followed up every other year for 8 years. Participants with axial length measurements at baseline (2011 or 2012) and at least 1 follow-up visit were included. Participants were grouped according to baseline age as children and adolescents (7 to <18 years), young adults (18 to <40 years), and older adults (≥40 to 70 years). Data were analyzed from November 1, 2022, to June 1, 2023. EXPOSURE High myopia (spherical power ≤−6.00 diopters). MAIN OUTCOMES AND MEASURES Longitudinal axial elongation trajectories were identified by cluster analysis. Axial elongation rates were calculated by linear mixed-effects models. A 2-sided P < .05 was defined as statistically significant. RESULTS A total of 793 participants (median [range] age, 17.8 [6.8-69.7] years; 418 females [52.7%]) and 1586 eyes were included in the analyses. Mean axial elongation rates were 0.46 mm/y (95% CI, 0.44-0.48 mm/y) for children and adolescents, 0.07 mm/y (95% CI, 0.06-0.09 mm/y) for young adults, and 0.13 mm/y (95% CI, 0.07-0.19 mm/y) for older adults. Cluster analysis identified 3 axial elongation trajectories, with the stable, moderate, and rapid progression trajectories having mean axial elongation rates of 0.02 mm/y (95% CI, 0.01-0.02 mm/y), 0.12 mm/y (95% CI, 0.11-0.13 mm/y), and 0.38 mm/y (95% CI, 0.35-0.42 mm/y), respectively. At 8 years of follow-up, compared with the stable progression trajectory, the rapid progression trajectory was associated with a 6.92 times higher risk of developing pathological myopic macular degeneration (defined as diffuse or patchy chorioretinal atrophy or macular atrophy; odds ratio, 6.92 [95% CI, 1.07-44.60]; P =.04), and it was associated with a 0.032 logMAR decrease in best-corrected visual acuity (β = 0.032 [95% CI, 0.001-0.063]; P =.04). CONCLUSIONS AND RELEVANCE The findings of this 8-year follow-up study suggest that axial length in high myopia continues to increase from childhood to late adulthood following 3 distinct trajectories. At 8 years of follow-up, the rapid progression trajectory was associated with a higher risk of developing pathological myopic macular degeneration and poorer best-corrected visual acuity compared with the stable progression trajectory. These distinct axial elongation trajectories could prove valuable for early identification and intervention for high-risk individuals.
UR - http://www.scopus.com/inward/record.url?scp=85181490433&partnerID=8YFLogxK
U2 - 10.1001/jamaophthalmol.2023.5835
DO - 10.1001/jamaophthalmol.2023.5835
M3 - Journal article
C2 - 38153745
AN - SCOPUS:85181490433
SN - 2168-6165
VL - 142
SP - 87
EP - 94
JO - JAMA Ophthalmology
JF - JAMA Ophthalmology
IS - 2
ER -